Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineProtection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein geneUse of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsDisulfide bond structure of glycoprotein D of herpes simplex virus types 1 and 2Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virusExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVAThe impact of new technologies on vaccine development.Vaccine technology: looking to the future.Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectorsHepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus.Herpes simplex viruses: is a vaccine tenable?Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.Vaccinia virus vectors: new strategies for producing recombinant vaccines.Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.New hepatitis B vaccines.Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.Mapping of the genes coding for the two major vaccinia virus core polypeptides.NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors.Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoproteinOral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenzaOverlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHC restriction elicited, and functional evidence for antigen-Ia interactionVaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence.Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytesReplication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.Gene therapy for viral hepatitis.Limited expression of poliovirus by vaccinia virus recombinants due to inhibition of the vector by proteinase 2A.Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virusFine mapping of antigenic site II of herpes simplex virus glycoprotein DExpression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virionsSynthetic glycoprotein D-related peptides protect mice against herpes simplex virus challengeHerpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus.Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.Expression of herpes simplex virus type 1 glycoprotein D deletion mutants in mammalian cellsThe contribution of cysteine residues to antigenicity and extent of processing of herpes simplex virus type 1 glycoprotein DAntigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutantsProphylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusLocalization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blottingMechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells.
P2860
Q21089976-6D19017D-BAFC-4355-88FE-4D85D79EEA88Q24606451-05508F1D-7616-4F25-9B93-2E8CDD2BD3ABQ26746915-146CD3EE-E92F-44DF-90BC-260D60F040BAQ27486188-886215D0-E901-4D3C-9EC3-466285563894Q27486585-304ACA08-7ABA-4563-ACC3-E49985F9C3FDQ28727937-E6660952-31B5-4822-9F14-A4C6CFB9ECA1Q30411839-D7F21DAE-C863-42FE-B976-05D31E6F8052Q33603392-6FB0AE9B-BC1E-4BA0-BCDF-1DD8FF54CEBAQ33879343-9580DC6D-B383-4B52-8D01-82C38B3C5CDCQ33926692-64F04552-04BD-499D-8566-496988F34391Q34139375-D5B0AF85-1D0A-4094-8D36-79E96455B368Q34162769-1EDBEEB6-C31A-492A-A775-1473B0D75F39Q34211635-9188ABE3-5D5A-4FCB-91F7-73DA8F327E71Q34340404-A2B438FE-E3D9-4D23-8BFF-A18E05AFE2B6Q34490083-E51F9D92-9A6D-46D9-B298-3AFCE8D63D9EQ34636530-0351D1B8-22F0-4034-8BE7-3A7EC8C3EED2Q35286494-61EB8644-9002-4274-A491-73C7655CF8C8Q35519418-D9E0B9AE-381D-4CD6-AB5B-98326EE89250Q35585367-7EDA2EC5-B98F-4D64-990D-3986D806F2DFQ35596022-0EB27655-CCE5-4FD8-8535-50C1B15E6858Q35868774-8C8DB16B-6FBB-47DC-8B90-56C230433F14Q36354522-CC2BAA68-B586-43A3-B740-54583A0DD328Q36523222-84108D7C-5E1B-487E-BF23-63EE5DE235C2Q36633955-818A149C-0BFE-4937-A138-E20F552F6EE2Q36686845-98E7EC24-AAB8-4F97-BB9D-ABC8C0B018ADQ36708296-F2821485-9F19-4901-A8BC-CA9DF97CFFF7Q36802770-A9B73C30-AE62-4B7E-B48E-DA3B72E97383Q36827447-D09EB68C-FB86-4573-95A5-124730C56363Q36827612-1FD23690-3328-441E-8AB7-BDA8B2B6008CQ36830970-D30E0AB5-4D54-4894-B0CA-832BD117939FQ36851214-3D5B9D87-03D8-45E0-946D-50C00925F1B0Q36855019-311C7BE7-30F3-49A7-B122-984F233FBF3EQ36865265-F32A3CC4-AACF-4BFC-A629-899417456D71Q36866619-84EE5F6F-FF42-4BD5-AD95-CD563C8AD3EBQ36868575-9A1F7A0E-3DC8-48B6-A2C1-6F39F1F65909Q36868606-F3E3F571-244F-4C14-B3BD-975CDE0ADDF3Q36872389-DB48E79F-DFBC-463D-88AF-B30D8D52013FQ36879345-02AEF333-C446-4D19-852F-4030D504D977Q36883752-5C08EDAF-B677-4165-AA77-53B30AD21F8EQ36885383-327BBC2F-D4BE-4F10-99FA-86C7D0493BB1
P2860
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Construction of live vaccines ...... simplex virus glycoprotein D.
@ast
Construction of live vaccines ...... simplex virus glycoprotein D.
@en
type
label
Construction of live vaccines ...... simplex virus glycoprotein D.
@ast
Construction of live vaccines ...... simplex virus glycoprotein D.
@en
prefLabel
Construction of live vaccines ...... simplex virus glycoprotein D.
@ast
Construction of live vaccines ...... simplex virus glycoprotein D.
@en
P2093
P2860
P356
P1476
Construction of live vaccines ...... simplex virus glycoprotein D.
@en
P2093
B R Lipinskas
C Samsonoff
D Panicali
E Paoletti
P2860
P304
P356
10.1073/PNAS.81.1.193
P407
P577
1984-01-01T00:00:00Z